Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.

Original languageEnglish
Pages (from-to)403-406
Number of pages4
JournalJournal of NeuroVirology
Issue number5
StatePublished - Oct 2006


  • CD4+ cell
  • HIV
  • Latent virus
  • Valproic acid
  • Viral load


Dive into the research topics of 'Valproic acid does not affect markers of human immunodeficiency virus disease progression'. Together they form a unique fingerprint.

Cite this